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Summary.-Leucocyte-migration-inhibition test was used to study the immune
reactions of leucocytes from 136 colorectal cancer patients, 43 patients with non-
cancerous chronic colorectal diseases and 82 controls, with saline extracts of HT29
line.
A positive inhibition was found in only 43o% of colorectal cancer patients. It was
higher in carcinomas of limited extension than in invasive ones (64% against 39%0). Furthermore, operation by itself had a depressive effect on the reaction, as the
positivity in 25 patients tested twice was 64% before operation and 32% after.
Leucocytes from patients with non-cancerous chronic colorectal diseases gave
many positive reactions (650,). The percentage of positivity was about the same for
diseases with high, low or no risk of cancerization. Hence the antigen(s) of tumour
extracts that react with patient's leucocytes are, at least partially, unrelated to cancer.
MANY authors have tried to demon-
strate acellularimmune response to cancer-
associated antigens in cancer patients.
They have often used the leucocyte-
migration-inhibition (LMI) test, a well
standardized and reproducible method
(Boodie et al., 1975; Cochran et al., 1972;
Elias et al., 1977; Guillou & Giles, 1973;
Kjaer, 1975, 1976; MacCoy et al., 1976,
1977; Zoller et al., 1977a, 1977b). As an
antigen source, they have taken extracts
of either surgical tumours or established
cell lines of tumour origin, these extracts,
always crude, being prepared with saline
or 3M KCI.
In a preliminary work (Burtin et al.,
1977) we compared the efficiency of
extracts of colonic primary tumours with
those of the HT29 cell line, for testing
leucocytes of patients with colorectal
carcinoma, and concluded that the latter
gave the best results. Furthermore, the
reproducibility and the absence of micro-
bial infection made them suitable for
LMI tests. Hence we studied the reactivity
of leucocytes of 68 colorectal carcinoma
patients with HT29 extract, and found
45%0 positive reactions. The percentage
of positivity was 9% and 40o% for leuco-
cytes of patients with respectively gyn-
aecological and gastro-intestinal carcino-
mas with the same extract.
We continued this study on a larger
series of cancer patients and control
subjects, with two aims: to explain the
reasons for many negative tests, and to
explore the specificity of the reaction,
i.e. its possible diagnostic value.
MATERIAL AND METHODS
(A) Antigen preparation.-The HT29 line
was obtained courtesy of Dr J. Fogh (Sloan-
Kettering Institute, Rye, New York, U.S.A.)
and cultured for several years by one of us.
Previous work (von Kleist et al., 1975, and
unpublished resuilts) showed that its cells
retained the ability to synthesize several
antigens already described in primary colonic
adenocarcinomas, such as carcinoembryonic
antigen (CEA), non-specific cross-reacting
antigens (NCA and NCA 2) and membrane-
associated tissue autoantigen (MTA).P. BURTIN ET AL.
HT29 cells were cultured in flat-bottomed
glass bottles in McCoy 5a medium, supple-
mented with 15% foetal calf serum. Absence
of mycoplasmas was checked regularly.
After 7 days of culture, the cells were harves-
ted by scraping with a rubber policeman,
followed by centrifugation. After 3 washings
with PBS, they were frozen and thawed
several times, and then sonicated for 2 x
90-second periods in a Bronson sonifier at an
energy of 50 watts.
The crude extract w,as either used as such,
or centrifuged at 100,000 g for 30 min in the
cold. The protein content of both the crude
extract and the supernatant was determined
by Lowry's method.
(B) Blood samples.-Blood samples were
obtained from:
(i) 136 patients with colonic or rectal
adenocarcinoma, always histologically pro-
ven. Blood was taken during either the pre-
or post-operative (1-15 days post-operative)
periods; in 25 patients, it was taken during
both.
(ii) 43 patients with non-malignant intes-
tinal disease: ulcerative colitis (11), Crohn's
disease (9), familial polyposis (7), polyps
(7), diverticular sigmoiditis (7) lipoma (1)
and inflammatory pseudotumour (1).
(iii) 82 regular blood donors.
Some patients and controls already studied
in our previous xvork were included in this
series.
To each heparinized 20 ml blood sample,
5 ml of Plasmagel (Roger Bellon, France) was
added. After a sedimentation period of
45 min at 37°C, the supernatant was carefully
pipetted off. The white cells m-ere collected
by centrifugation at 400 g, washed x 3 with
Waymouth's medium and diluted to 5 x 107
cells/ml with the same medium.
(C) The leucocyte-migration-inhibition meth-
od.-We used the classical Bendixen &
Soborg method (1967) modified by Beaulieu
(1976) as described in our previous work
(Burtin et al., 1977). The main feature of this
technique is the use of a capillary haemato-
crit tube as the migration chamber, allowing
a longitudinal migration of the white cells,
with an easy and accurate reading. The
first step was incubation of the white cells,
3 x 106 in 60 ul of Waymouth's medium,
for 2 h at 37°C, with different dilutions ofthe
antigen. The controls contained the medium
alone.
The cells were then suspended by light
shaking in the surrounding medium, in
which were placed vertically 4 flexible
plastic capillaries (Polypropylene PP 20,
Portex, Hythe, England) made rigid by
their inclusion in glass haematocrit capillaries
(internal diameter 1 1-1 P2 mm, Brand,
Werpheim/Main, Germany).
These plastic capillaries were filled by
aspiration under vacuum, centrifuged at
1800 g for 5 min, and cut at the upper limit
of the white layer. They were then intro-
duced into new glass capillaries similar to
the preceding ones, that were filled with
antigen diluted in Waymouth's medium,
supplemented with 10% decomplemented
AB serum, penicillin (200 yug/ml) and strepto-
mycin (50 ,ug/ml).
The migration lasted 18 h at 37°C in
an incubator with 500 CO2 atmosphere. It was
only longitudinal, due to the form of the
migration chamber. The distance migrated
was measured with a micrometric scale
placed in the eyepiece of a binocular
magnifier (BBT, Paris, France).
The leucocytes from each blood sample
were tested with 4 concentrations of either
HT29 crude extract or supernatant at 20, 40,
60 and 80 jug protein/ml. The extract was
tested with leucocytes from 74 patients with
colorectal cancer and 15 with non-cancerous
intestinal diseases. The supernatant was
tested wiith leucocytes from 62 colorectal-
cancer patients and 28 patients with non-
cancerous intestinal diseases. Each experi-
ment was performed 4 times. In control tubes,
no antigen was added to the medium. The
migration index was calculated as the ratio:
mean migration in presence of antigen MlI mean migration in controls
(D) Tunmour staging.-In order to have
the most precise information, two staging
methods were used: Dukes' classification
(1958) based mainly on the local extension of
the cancer and TNM classification, related
to the size ofthe tumour as well as its regional
and systemic dissemination.
(E) Statistical analysis.-We selected for
each antigenic concentration the cut-off
value of MI in 41 blood donors by the tenth
per centile test. In each group of patients,
and for each antigenic concentration, we
determined the percentage of patients
with an MI below the cut-off value and we
compared this with 10% by the x2 test.
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We considered as positive in LMI-test
patients with an MI at least below the
cut-off value, for one antigenic concentration
of one extract.
RESULTS
The leucocytes of the 136 patients with
colorectal carcinoma were reacted with
HT29 extract (crude extract or super-
natant) in the LMI test. Results were
reproducible, the standard deviation be-
tween the 4 replicates generally being
around 5%.
i
4;
0,I
cm
I.-
x
I.-
E
3:
x
c
m
p
4<
m
c
r.
120 e
li:
1D9 ',
010 0 0 o
* -0-*
.-:z
so t
70
BLOOD COLORECTAL NON-MiIALIGNANT
DONORS CANCER INTESTINAL 4140(10'1.) PATIENTS DISEASES
19174 UV6) 6115(40Z)
FIG. 3.-Scattergram of the reactivity with
HT29 crude extract (T) at a concentration
of 60 ,ug/ml, of leucocytes from normal
donors and patients with colorectal cancer
or non-cancerous intestinal disease.
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FIG. 1.-Scattergram of the reactivity with
HT29 crude extract (T) at a concentration
of 80 ,ug/ml, of leucocytes from normal
donors and patients with colorectal cancer
or non-cancerous intestinal disease.
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FIG 2 Scattergram of the reactivity with
H-T29 supernatant (S) at a concentration of
80 lzg/ml, ofleucocytes from normal doniors
and patients with colorectal cancer or non-
cancerous intestinal disease.
e
i
0
x
Z
a1-
0.~~~~~~~~~~~~J
BLOOD COLOECTA.NONM
DLONORS CANORCERL IONTESTIGNANT
4b40(10) PATIENTS DISEASES
1S/S2 31304) 15/28195b
FIG. 4. Scattergram of the reactivity with
HT29 supernatant (S) at concentration of
60 ,ug/ml, of leucocytes from normal
donors and patients with colorectq cancer
or non-cancerous intestinal disease.
When results obtained with cancer
leucocytes were compared with those of
controls for each concentration of either
extract, a significant difference was found
for 80 and 60 ,tg/ml (Figs. 1-4), but not
for smaller concentrations of antigen.
Therefore, we considered only results
obtained with the 2 highest concentra-
tions. We observed an inhibition in 37.8%
in leucocytes tested with crude extract,
and 50% in leucocytes tested with
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TABLE. Incidence ofpositire LMI tests in colorectal cancer
and other intestinal diseases
CondlitionI
Colorectal cancer
Limitedi (A.Bl)
Invasive (B2.C1.C2)
Noin-malignant intestinal diseases
(1) No risk of cancerization
Sigmoiditis
Lipoma
Inflammatorv pseulotimotr
(2) Low risk
Crohn's disease
Ulcerative colitis
Polyps
(3) High risk
Familial polyposis
Number of positive reactions/
nuimber of patieits (°/0)
59/136 (43)
16/25 (64) IP 0O05 43/111 (39) f
28/43 (65)
5/17 )
1/1 S6/19 (66)
0/1 J
6/9 1
6/11 17/27 (63)
5/7 J
5/7 (71)
supernatant. Results in both series were
not statistically different, so we summed
them: we thus obtained inhibition in
59/136 cases, i.e. 4300 (Table). This
percentage is very similar to that already
published (45%) and found in a smaller
series of leucocytes tested only with
HT29 crude extract.
Stimulation of migration was obtained
less frequently, i.e. in 15-2000 of cases.
The difference from controls, if any, was
always weak and never significant.
We rarely saw leucocytes of the same
patient being stimulated by low con-
centrations of antigen, and inhibited by
higher concentrations, or vice-versa.
In some experiments, where we used
very high extract concentrations, i.e.
1 mg/ml in addition to the usual dilu-
tions, the results did not change. Our
data are in disagreement with those of
Zoller et al. (1977b) and Kjaer (1975).
Tumour stagtng in LMI tests
The main parameters of TNM classifica-
tion gave no major clue to the significance
of LMI tests; there was a trend to a
decreasing number of positive reactions
when tumours were large, lymph nodes
were invaded and/or distant metastasis
were present, but this had no statistical
significance.
On the contrary, we could attribute an
important role to local tumour extension,
when we compared the reactions given by
the leucocytes of colonic or rectal cancer
of limited extension (Stages A and BJ in
Dukes' classification) with those of other
cases, i.e. extensive cancers (Dukes' B2-C).
The dividing line between these groups
was whether or not the tumour invaded
the serosa. As shown in the Table, the
percentage of positives was significantly
different betwveen these groups (P < 0.05):
60)!
30)!
64 '.
P < 0 .05
32 z.
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64% for the first group and 390o for the
second. It will be noticed that this last
percentage differs only slightly from that
(430) obtained in the whole series of
colorectal carcinomas. This is not surpris-
ing, due to the high number 111/136
(81.5%) of patients having an extensive
carcinoma.
It is thus clear that invasion of the
serosa by the tumour leads to a decreased
positivity in the LMI test.
Influence of surgery on LMI tests
This was studied in the 25 patients
whose leucocytes were tested before and
after operation. Sixteen of these patients
(64%) were positive before surgery, and
only 8 (32%) after (Fig. 5). The difference
between these values was significant
(P < 0 05). Such a change was seen in
patients with or without metastasis.
LMJ test in non-caqncerouas intestinal
diseases
Leucocyte migration was inhibited in
65% of the patients with these diseases
(Table). This percentage was significantly
higher (P < 0.05) than that seen in
colorectal carcinomas (43%), but com-
parable to that found in carcinomas of
limited extension (640o). We attempted
to consider separately the cases where the
disease had a high, a low or no risk of
cancerization: LMI test gave about the
same percentage of positive reactions in
the 3 categories (Table). These results must
be taken cautiously, owing to the small
number of cases in each category.
D)ISCUSSION
Our data lead us to consider 3 main
points:
(1) The reason(s) for the many negative
r-esults when reacting cancer leucocytes
with HT29 extract in the LMI test. A
technical explanation, such as missing
the useful antigenic concentration(s) is
likely in some cases. But many negative
results have other explanations.
Tumour progression is one of them.
Once the serosa is invaded, the percentage
of positive reactions decreases signifi-
cantly. This result, never before reported,
may correlate with the well-known in-
creased clinical risk of extensive tumours.
One explanation for the decreased re-
activity could be an antigenic overload
which might neutralize sensitized lympho-
cytes. To test this hypothesis we washed
the leucocytes 10 times to remove a
possible surface-bound antigen, as re-
ported by Currie & Basham (1972) and
Kjaer (1976). We were never able to
transform negative results into positives
by this method.
It is also worth remembering that in
experimental models, large tumours in-
duce more immune suppression than do
others, and this is also true' for human
tumours (Good, 1975).
Another important feature is that
surgery leads to a marked decrease in
migration inhibition. Tumour removal by
itself does not seem to be the major
cause, as palliative operations had the
same influence. An antigenic overloading
due to tissue destruction during operation
is unlikely. Hence, the most logical
explanation for the small number of posi-
tive LMI results during the postoperative
period (at least for the few days between
the operation and the test) is a suppres-
sive influence of surgery itself, the main
factor possibly being the anaesthesia
(Nunn et al., 1970). Several years ago,
Cochran et al. (1972) reported similar
data.
(2) We have now to comment on the
high percentage of migration inhibitions
obtained when leucocytes of patients with
a non-cancerous chronic intestinal disease
were tested with HT29 extract. Our data
show that the LMI test is of no value for
the diagnosis of colorectal carcinoma.
They do not allow any conclusions as to
the possible cancerization of chronic
intestinal disease, as diseases with or
without cancerization risk gave about as
many positive tests.
Our results seem to contradict those
ofother groups who have found specificity
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in their LMI tests. Yet some authors
(MacCoy et al., 1976, 1977; Boodie et al.,
1975) simply compared leucocytes from
patients with carcinoma of a specific
anatomical site (e.g. breast or lung) with
those from patients with carcinoma of a
second site, in terms of reactivity with
extracts of tumours of the first site. They
obtained very different results from the
two groups, and logically concluded that
they had an organ-type specificity. Yet
they did not take leucocytes of non-
cancerous diseases of the same organs as
controls, so that their results cannot be
compared to ours.
On the contrary, Guillou & Giles (1973),
Zoller et al. (1977b), Elias et al. (1977)
used a methodology much closer to our
own. In Guillou and Giles' experiments,
there was a significant difference between
cancer and control leucocytes in their
reactivity with colonic cancer extracts.
Yet 8/22 cancer leucocytes reacted with
normal colonic mucosa extract, hence the
nature of sensitizing antigen(s) was ques-
tioned by the authors. Elias et al. (1977)
compared the reactivity of colon-cancer
leucocytes with extracts of autologous
tumours and peritumoral mucosae. They
found a stronger inhibition with the
former. Their results were clearcut and
could indicate the existence of cancer
antigens, at least of individual specificity.
This conclusion could be debated, as the
authors used the same concentration
(100 jug/ml) of tumoral and non-tumoral
extracts. They could have missed positive
reactions that would have been obtained
with higher amounts of non-tumoral
colonic mucosa extract.
Zoller et al. (1977b) used very high
amounts of KCI extracts of primary
colonic tumours in their LMI tests. They
found very few cases of reactivity among
control leucocytes, and a high percentage
in cancer leucocytes (when summing both
inhibition and stimulation). They con-
sidered as "negative", leucocytes not
reacting with more than one or two out of
5 cancer extracts studied in parallel. On
the contrary, "positive" leucocytes, gener-
ally from cancer patients, reacted with at
least 3 of these extracts. This way of
reasoning does not exclude the possibility
of tissue antigens being present in cancer
extracts and contributing to the sensi-
tization of cancer as well as normal
leucocytes. Furthermore, the authors not-
ed a higher percentage of positivity (yet
much lower than that of colon-cancer
leucocytes) with leucocytes of chronic
intestinal diseases, in comparison to those
of normal controls. In another study
(Zoller et al., 1977a) of the LMI test in
gastric-carcinoma patients, the same
authors observed 530o positives with
leucocytes of atrophic gastritis. Here
again, a chronic disease of the mucosa,
sometimes but not always at a stage of
precancerization, showed a frequent sensi-
tization to antigens contained in cancer
extracts.
(3) The last point to be discussed is the
nature of the sensitizing antigens present
in HT29 extract. Are they cancer-associa-
ted, if not cancer-specific? Or do we
actually deal only with tissue com-
ponents as sensitizing antigens, as in the
auto-immune diseases? One couLld admit
either that we have only tissue antigens
in HT29 extract, or that we have a mixture
of normal and cancer antigens. In this
case, the reactivity to the former antigens
would often mask that to the latter. No
conclusion can be drawn as long as
crude extracts are used. A fractionation
ofthese extracts is thus necessary. A more
refined LMI test, probably based on a
two-step method, would help to study
fractionation products.
If HT29 extract contained only tissue
antigens, would it be possible to have
better results with other antigenic
material? Primary tumours might be
satisfactory, as judged by the data re-
ported by Zoller et al. (1977b), but the
results mentioned in our previous article
(Burtin et al., 1977) did not confirm this
thesis. Other established lines could yield
more specific extracts. So we tested 2
other colorectal lines, HRT18 and HCT8,
kindly furnished by Dr R. H. Schultz
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(NCI, Bethesda, U.S.A.). In fact, we had
no more positive results with HCT8 than
the HT29 extract. Inversely HRT18
extract gave a high percentage of LMI,
whatever the disease of the patient:
carcinoma of the colon or another organ,
non-intestinal cancerous disease, etc. Thus,
we did not find an antigenic extract
better than HT29.
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